RDHL · RedHill Biopharma Ltd.

This 6-K discloses a high-materiality R&D advancement for RedHill’s lead Crohn’s disease program, RHB-204—a next-generation reformulation of RHB-104 designed to improve tolerability and adherence while preserving anti-MAP activity. The in vitro comparability data bridges preclinical validation to clinical development, directly supporting the planned Phase 2 trial—the first ever in a prospectively defined MAP-positive CD population. That trial design is strategically pivotal: it addresses a longstanding hurdle in MAP-targeted therapy (lack of rapid, accurate diagnostics) via collaborations with European academic centers for cutting-edge MAP detection, thereby de-risking patient selection and potentially enabling a more efficient regulatory path. Regulatory incentives are robust and fully disclosed: RHB-204 inherits RHB-104’s FDA Fast Track, Orphan, and QIDP designations—conferring up to 12 years of US exclusivity—and holds EU Orphan status for 10 years, all underpinned by patent protection until 2041. Critically, the lower-dose active ingredient profile suggests a tangible safety advantage over RHB-104, which could translate into differentiated positioning against costly, injectable biologics with black box warnings. While no financial or commercial metrics are provided, the disclosure anchors RHB-204’s value proposition in validated clinical efficacy (from RHB-104’s Phase 3), strong IP, and a novel, biomarker-enriched development pathway—making this a foundational update for investors assessing RedHill’s near-term clinical catalysts and long-term commercial optionality in the $19.1B Crohn’s disease market.